1     
CONTROLLED SUBSTANCES REVISIONS

2     
2020 GENERAL SESSION

3     
STATE OF UTAH

4     
Chief Sponsor: Paul Ray

5     
Senate Sponsor: Allen M. Christensen

6     

7     LONG TITLE
8     Committee Note:
9          The Health and Human Services Interim Committee recommended this bill.
10               Legislative Vote:     13 voting for     0 voting against     4 absent
11     General Description:
12          This bill amends the list of controlled substances and the composition of the Controlled
13     Substances Advisory Committee.
14     Highlighted Provisions:
15          This bill:
16          ▸     adds a substance to the listed controlled substances in the Utah Controlled
17     Substances Act;
18          ▸     amends the composition of the Controlled Substances Advisory Committee; and
19          ▸     makes technical changes.
20     Money Appropriated in this Bill:
21          None
22     Other Special Clauses:
23          None
24     Utah Code Sections Affected:
25     AMENDS:
26          58-37-4.2, as last amended by Laws of Utah 2018, Chapter 146
27          58-38a-201, as last amended by Laws of Utah 2011, Chapter 60
28          58-38a-202, as last amended by Laws of Utah 2011, Chapter 60
29     

30     Be it enacted by the Legislature of the state of Utah:
31          Section 1. Section 58-37-4.2 is amended to read:
32          58-37-4.2. Listed controlled substances.
33          The following substances, their analogs, homologs, and synthetic equivalents are listed
34     controlled substances:
35          (1) AB-001;
36          (2) AB-PINACA;
37     N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide;
38          (3) AB-FUBINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)
39     methyl]-1H-indazole-3-carboxamide;
40          (4) AB-CHMINACA
41     (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);
42          (5) ADB-CHMINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
43     (cyclohexylmethyl)indazole-3-carboxamide);
44          (6) ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1oxobutan-2-yl)-1-
45     (4-fluorobenzyl)-1H-indazole-3-caboxamide);
46          (7) AKB48;
47          (8) alpha-Pyrrolidinohexanophenone (alpha-PHP)
48     (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
49          (9) alpha-Pyrrolidinovalerophenone (alpha-PVP);
50          (10) AM-694 (1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone);
51          (11) AM-1248;
52          (12) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);
53          (13) AM-2233;
54          (14) AM-679;
55          (15) A796,260;
56          (16) Butylone;
57          (17) CP 47,497 and its C6, C8, and C9 homologs (2-[(1R,3S)-3-hydroxycyclohexyl]
58     -5-(2-methyloctan-2-yl)phenol);
59          (18) Diisopropyltryptamine (DiPT);
60          (19) Ethylone;
61          (20) Ethylphenidate;
62          (21) Fluoroisocathinone;
63          (22) Fluoromethamphetamine;
64          (23) Fluoromethcathinone;
65          (24) FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate;
66          (25) HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
67     -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
68          (26) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
69     methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
70          (27) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
71          (28) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as
72     1-Pentyl-3-(1-naphthoyl)indole};
73          (29) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;
74          (30) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as
75     1-Butyl-3-(1-naphthoyl)indole};
76          (31) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
77          (32) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
78          (33) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
79          (34) JWH-203; 1-pentyl-3-(2-chlorophenylacetyl)indole;
80          (35) JWH-210; 4-ethyl-1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone;
81          (36) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
82          (37) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
83          (38) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
84          (39) MAM-2201;
85          (40) MAM-2201;
86     (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone;
87          (41) Methoxetamine;
88          (42) Naphyrone;
89          (43) PB-22; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester;
90          (44) Pentedrone;
91          (45) Pentylone;
92          (46) RCS-4; 1-pentyl-3-(4-methoxybenzoyl)indole;
93          (47) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also known as
94     BTW-8 and SR-18};
95          (48) STS-135;
96          (49) UR-144;
97          (50) UR-144 N-(5-chloropentyl) analog;
98          (51) XLR11;
99          (52) 2C-C;
100          (53) 2C-D;
101          (54) 2C-E;
102          (55) 2C-H;
103          (56) 2C-I;
104          (57) 2C-N;
105          (58) 2C-P;
106          (59) 2C-T-2;
107          (60) 2C-T-4;
108          (61) 2NE1;
109          (62) 25I-NBOMe;
110          (63) 2,5-Dimethoxy-4-chloroamphetamine (DOC);
111          (64) 4-Fluoro MDMB-BUTINACA (Methyl
112     2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate);
113          [(64)] (65) 4-methylmethcathinone {also known as mephedrone};
114          [(65)] (66) 3,4-methylenedioxypyrovalerone {also known as MDPV};
115          [(66)] (67) 3,4-Methylenedioxymethcathinone {also known as methylone};
116          [(67)] (68) 4-methoxymethcathinone;
117          [(68)] (69) 4-Methyl-alpha-pyrrolidinopropiophenone;
118          [(69)] (70) 4-Methylethcathinone;
119          [(70)] (71) 5F-AKB48;
120     1-(5-flouropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3- carboxamide;
121          [(71)] (72) 5-Fluoro ADB (Methyl
122     N-{[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}-3-methyl-valinate);
123          [(72)] (73) 5-Fluoro AMB (Methyl
124     N-{[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl}valinate);
125          [(73)] (74) 5-fluoro-PB-22; 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid
126     8-quinolinyl ester;
127          [(74)] (75) 5-Iodo-2-aminoindane (5-IAI);
128          [(75)] (76) 5-MeO-DALT;
129          [(76)] (77) 25B-NBOMe; 2-(r-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
130     methyl]ethanamine;
131          [(77)] (78) 25C-NBOMe; 2-(4Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
132     methyl]ethanamine; and
133          [(78)] (79) 25H-NBOMe;
134     2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine.
135          Section 2. Section 58-38a-201 is amended to read:
136          58-38a-201. Controlled Substances Advisory Committee.
137          There is created within the Division of Occupational and Professional Licensing the
138     Controlled Substances Advisory Committee. The committee consists of:
139          (1) the director of the Department of Health or the director's designee;
140          (2) the State Medical Examiner or the examiner's designee;
141          (3) the commissioner of the Department of Public Safety or the commissioner's
142     designee;
143          (4) the director of the Bureau of Forensic Services created in Section 53-10-401, or the
144     director's designee;
145          (5) the director of the Utah Poison Control Center or the director's designee;
146          [(4)] (6) one physician who is a member of the Physicians Licensing Board and is
147     designated by that board;
148          [(5)] (7) one pharmacist who is a member of the Utah State Board of Pharmacy and is
149     designated by that board;
150          [(6)] (8) one dentist who is a member of the Dentist and Dental Hygienist Licensing
151     Board and is designated by that board;
152          [(7)] (9) one physician who is currently licensed and practicing in the state, to be
153     appointed by the governor;
154          [(8)] (10) one psychiatrist who is currently licensed and practicing in the state, to be
155     appointed by the governor;
156          [(9)] (11) one individual with expertise in substance abuse addiction, to be appointed
157     by the governor;
158          [(10)] (12) one representative from the Statewide Association of Prosecutors, to be
159     designated by that association;
160          [(11)] (13) one naturopathic physician who is currently licensed and practicing in the
161     state, to be appointed by the governor;
162          [(12)] (14) one advanced practice registered nurse who is currently licensed and
163     practicing in this state, to be appointed by the governor; and
164          [(13)] (15) one member of the public, to be appointed by the governor.
165          Section 3. Section 58-38a-202 is amended to read:
166          58-38a-202. Terms of committee service.
167          (1) (a) Members of the advisory committee shall serve terms of four years, except that
168     the members under Subsections 58-38a-201(1), (2), [and] (3), and (4) shall serve during their
169     terms as appointed officials.
170          (b) Vacancies in the committee occurring otherwise than by the expiration of a term
171     shall be filled for the unexpired term in the same manner as original appointments.
172          (2) A member may not receive compensation or benefits for the member's service, but
173     may receive per diem and travel expenses in accordance with:
174          (a) Section 63A-3-106;
175          (b) Section 63A-3-107; and
176          (c) rules made by the Division of Finance pursuant to Sections 63A-3-106 and
177     63A-3-107.
178          (3) (a) The director of the Department of Health, or the director's designee, is the chair
179     of the committee.
180          (b) The advisory committee meets at the call of the chair or at the call of a majority of
181     the committee members.
182          (c) The advisory committee meets annually and more often as required to carry out its
183     duties under this chapter.
184          (d) Seven members of the advisory committee constitute a quorum.
185          (e) Action by the committee requires a majority vote of a quorum.